Long Covid presents a complex challenge for clinicians, as many patients exhibit a variety of persistent symptoms suggestive of immune dysregulation. Growing interest in immunotherapies and monoclonal antibodies highlights potential benefits for certain subsets of patients. However, evidence remains limited, necessitating caution and careful patient selection in treatment approaches.
Tag: rituximab long covid
Monoclonal Antibodies and Long Covid: What Shows Promise and What We Still Don’t Know
Long Covid presents challenges requiring a shift from symptom-based to immunological approaches, focusing on immune dysregulation and incomplete recovery. Monoclonal antibodies are explored for potential treatment, although evidence is inconsistent, highlighting the need for biomarkers for effective patient selection. Research remains essential for understanding Long Covid's complex biology.
Long Covid Journey 